Dyspnoea and worsening heart failure in patients with acute heart failure: Results from the Pre-RELAX-AHF study

European Journal of Heart Failure

Volumn 12, Issue 10, 2010, Pages 1130-1139

  Metra, Marco ^a   Teerlink, John R ^b   Felker, G Michael ^c   Greenberg, Barry H ^d   Filippatos, Gerasimos ^e   Ponikowski, Piotr ^f   Teichman, Sam L ^g   Unemori, Elaine ^g   Voors, Adriaan A ^h   Weatherley, Beth Davison ⁱ   Cotter, Gad ⁱ  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UCSD MEDICAL CENTER   (United States)

^e UNIVERSITY OF ATHENS   (Greece)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g Corthera Inc ^*  (United States)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ Momentum Research Inc   (United States)

Author keywords

Acute heart failure; Dyspnoea; Prognosis; Relaxin

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; FUROSEMIDE; HYDRALAZINE; LOOP DIURETIC AGENT; MILRINONE; NITRATE; RELAXIN;

ABNORMAL RESPIRATORY SOUND; ACUTE HEART FAILURE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CENTRAL VENOUS PRESSURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE COURSE; DYSPNEA; FEMALE; HEART FAILURE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VISUAL ANALOG SCALE; WEIGHT CHANGE;

AGED; AREA UNDER CURVE; DISEASE PROGRESSION; DYSPNEA; FEMALE; HEALTH STATUS INDICATORS; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; PAIN MEASUREMENT; PROGNOSIS; STATISTICS AS TOPIC;

EID: 77957234038     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq132     Document Type: Article

References (34)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, vanVeldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
2. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009;53: 557-573.
3. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90.
4. Metra M, Ponikowski P, Dickstein K, McMurray JJ, Gavazzi A, Bergh CH, Fraser AG, Jaarsma T, Pitsis A, Mohacsi P, Böhm M, Anker S, Dargie H, Brutsaert D, Komajda M, Heart Failure Association of the European Society of Cardiology. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2007;9:684-694
5. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-1540.
6. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I, VERITAS Investigators. Effects of tezosen-tan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009-2019.
7. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of Vaso-pressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-1343.
8. O'Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decom-pensated heart failure: observations from the IMPACT-HF registry. J Card Fail 2005;11:200-205.
9. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC, ADHERE Scientific Advisory Committee, Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006;47: 76-84.
10. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M, ADHERE Scientific Advisory Committee, Investigators. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007;49:1943-1950.
11. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM, Protect Steering Committee, Investigators, Coordinators. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008;14:631-640.
12. Mebazaa A, Pang PS, Tavares M, Collins SP, Storrow AB, Laribi S, Andre S, Courtney DM, Hasa J, Spinar J, Masip J, Peacock WF, Sliwa K, Gayat E, Filippatos G, Cleland JG, Gheorghiade M. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J 2010;31:832-841.
13. Hogg KJ, McMurray JJ. Evaluating dyspnoea in acute heart failure: progress at last!. Eur Heart J 2010;31:771-772.
14. Weatherley BD, Milo-Cotter O, Michael Felker G, Uriel N, Kaluski E, Vered Z, O'Connor CM, Adams KF, Cotter G. Early worsening heart failure in patients admitted with acute heart failure\a new outcome measure associated with long-term prognosis? Fundam Clin Pharmacol 2009;23:633-639.
15. Cotter G, Metra M, Weatherley BD, Dittrich HC, Massie BM, Ponikowski P, Bloomfield DM, O'Connor CM. Physician-Determined Worsening Heart Failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure\association with signs and symptoms, hospitalization duration, and 60-day outcomes. Cardiology 2009;115:29-36.
16. Torre-Amione G, Milo-Cotter O, Kaluski E, Perchenet L, Kobrin I, Frey A, Rund MM, Weatherley BD, Cotter G. Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome. J Card Fail 2009;15:639-644.
17. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006;8:105-110.
18. De Luca L, Mebazaa A, Filippatos G, Parissis JT, Böhm M, Voors AA, Nieminen M, Zannad F, Rhodes A, El-Banayosy A, Dickstein K, Gheorghiade M. Overview of emerging pharmacologic agents for acute heart failure syndromes. Eur J Heart Fail 2008;10:201-213.
19. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL, Cotter G. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multi-centre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;373:1429-1439.
20. Metra M, Teerlink JR, Voors AA, Felker GM, Milo-Cotter O, Weatherley B, Dittrich H, Cotter G. Vasodilators in the treatment of acute heart failure: what we know, what we don't. Heart Fail Rev 2009;14:299-307.
21. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ, ADHERE Scientific Advisory Committee, Study Group, Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005;293:572-580.
22. O'Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, Yancy CW, Young JB, Fonarow GC. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in-Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2008;156:662-673.
23. Harjola VP, Follath F, Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Hochadel M, Komajda M, Lopez-Sendon JL, Ponikowski P, Tavazzi L. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. Eur J Heart Fail 2010;12:239-248.
24. Stevenson LW, Hellkamp AS, Leier CV, Sopko G, Koelling T, Warnica JW, Abraham WT, Kasper EK, Rogers JG, Califf RM, Schramm EE, O'Connor CM. Changing preferences for survival after hospitalization with advanced heart failure. J Am Coll Cardiol 2008;52:1702-1708.
25. Teerlink JR. Dyspnea as an end point in clinical trials of therapies for acute decom-pensated heart failure. Am Heart J 2003;145(Suppl. 2):S26-S33.
26. Gheorghiade M, Adams KF, Cleland JG, Cotter G, Felker GM, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pang PS, Piña IL, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Stockbridge N, Acute Heart Failure Syndromes International Working Group. Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. Am Heart J 2009;157: 957-970.
27. Pang PS, Cleland JG, Teerlink JR, Collins SP, Lindsell CJ, Sopko G, Peacock WF, Fonarow GC, Aldeen AZ, Kirk JD, Storrow AB, Tavares M, Mebazaa A, Roland E, Massie BM, Maisel AS, Komajda M, Filippatos G, Gheorghiade M, Acute Heart Failure Syndromes International Working Group. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 2008;29:816-824.
28. Pang PS, Konstam MA, Krasa HB, Swedberg K, Zannad F, Blair JE, Zimmer C, Teerlink JR, Maggioni AP, Burnett JC Jr, Grinfeld L, Ouyang J, Udelson JE, Gheorghiade M, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J 2009;30:2233-2240.
29. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008;10:165-169.
30. Milo-Cotter O, Adams KF, O'Connor CM, Uriel N, Kaluski E, Felker GM, Weatherley B, Vered Z, Cotter G. Acute heart failure associated with high admission blood pressure\a distinct vascular disorder? Eur J Heart Fail 2007;9: 178-183.
31. Allen LA, Metra M, Milo-Cotter O, Filippatos G, Reisin LH, Bensimhon DR, Gronda EG, Colombo P, Felker GM, Cas LD, Kremastinos DT, O'Connor CM, Cotter G, Davison BA, Dittrich HC, Velazquez EJ. Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). J Card Fail 2008;14:777-784.
32. Metra M, Cleland JG, Davison Weatherley B, Dittrich HC, Givertz MM, Massie BM, O'Connor CM, Ponikowski P, Teerlink JR, Voors AA, Cotter G. Dyspnoea in Patients with Acute Heart Failure. An analysis of its clinical course, determinants and relationship to 60 day outcomes in the PROTECT pilot study. Eur J Heart Fail 2010;12:499-507.
33. Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, Adams KF Jr. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007;9:1064-1069.
34. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 2002;4:515-529.